To addressthese challenges and enable tumor-selective, stimuli-responsive delivery,we developed an LGP nanogel system for the encapsulation and controlledrelease of protein therapeutics such as GOx and TRAIL (Figure A). The gene discussed is HAO1; the disease is neoplasm.